B. Riley Securities Assumes Anika Therapeutics at Buy, Raises Price Target to $23

Benzinga Newsdesk www.benzinga.com Positive 71.3%

Neg 0% Neu 0% Pos 71.3%

B. Riley Securities analyst Madison El-Saadi assumes Anika Therapeutics (NASDAQ:ANIK) with a Buy rating and raises Price Target to $23.